Oculis Holding AG
NASDAQ:OCS
Relative Value
The Relative Value of one OCS stock under the Base Case scenario is hidden USD. Compared to the current market price of 27.28 USD, Oculis Holding AG is hidden .
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
OCS Competitors Multiples
Oculis Holding AG Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CH |
O
|
Oculis Holding AG
NASDAQ:OCS
|
1.6B USD | 0 | -12.5 | -14.3 | -14.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
944.6B USD | 14.5 | 45.8 | 30.9 | 32.9 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
585.1B USD | 6.2 | 21.8 | 15.2 | 18.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
262.8B CHF | 4.3 | 20.4 | 12 | 13.5 | |
| CH |
|
Novartis AG
SIX:NOVN
|
233.9B CHF | 5.3 | 21.5 | 13.3 | 17.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
223.2B GBP | 5.1 | 29.2 | 16.2 | 22.8 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
287.6B USD | 4.4 | 15.8 | 9.8 | 11.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.6 | 10.9 | 8 | 9.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
155.2B USD | 2.5 | 20 | 7.7 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
120.7B USD | 2.5 | 17.1 | 7.2 | 8.9 |